We are excited to announce that Andrew Hider has been selected to serve as Baxter’s next president and CEO.

Our annual Corporate Responsibility Report is now available; learn more about Baxter's efforts to make a meaningful difference around the world and across our company:  #BaxterGivesBack #CorporateResponsibility

Are you headed to the @AmDiabetesAssn's 85th Scientific Sessions this weekend? Stop by Booth #3112 to learn more about how we are advancing care. We hope to see you there! #ADASciSessions

Following Hurricane Helene’s impact on our North Cove manufacturing site, Baxter has removed allocations on virtually all impacted IV solution product codes. Learn more: #NorthCoveStrong

Today, we introduce a refreshed Baxter brand, marking a pivotal moment in our transformation. Now, as a more focused company, we are redefining healthcare delivery across the care journey. US-MD34-250020 (v1.0) 05/2025

Our Q1 2025 financial results are in. First quarter performance exceeded our previously issued guidance on both the top and bottom line.

Join us tomorrow at 7:30 a.m. CDT for our Q1 2025 earnings conference call webcast. Register here:

The Pediatric Academic Societies meeting, #PAS2025, is right around the corner! Interested in learning more about early nutrition? Sign up today to join our expert neonatologists for a discussion about neonatal refeeding syndrome:

It’s day two of #HIMSS25 and the Baxter team is still buzzing from this week's excitement, including the announcement of our first voice-activated solution. Join us at booth #4343 in the Venetian Expo to keep the conversation going.

At #HIMSS25? Join Baxter’s VP of Enterprise Technology Chris Gutmann as he shares the ins and outs of integrating medical devices with clinical systems, including the EHR. Two chances to join: Tuesday and Wednesday at 2:30 p.m. PST in Smart Connections Theater at Caesar’s Forum.

Our Q4 & FY 2024 financial results are in. Our performance and related strategic milestones reflect our growing momentum in pursuit of enhanced value for our stakeholders.

Join us tomorrow at 7:30 a.m. CST for our Q4 & FY 2024 earnings conference call webcast. Register here:

Following Hurricane Helene’s impact on our North Cove manufacturing site, our facility has returned to pre-hurricane production levels. Learn more: #NorthCoveStrong

Our strategic transformation & just-closed sale of our Kidney Care business culminate in a unique turning point for Baxter. Today we announced the retirement of chair & CEO Joe Almeida & Heather Knight's appointment as COO. Learn more in the announcement:

Our teams continue to make progress on the phased restart of operations in North Cove, and we restarted our 2nd IV solutions manufacturing line. This means ~50% of the site’s total pre-hurricane production is now online. #NorthCoveStrong

Today, the first truckloads of IV fluid products made post-Hurricane Helene left our North Cove facility, while HHS Secretary Becerra was onsite. We are grateful for the Secretary's leadership, and the support of @HHS, @FDA, @ASPR & the state of North Carolina. #NorthCoveStrong

Our third-quarter 2024 financial results are in. We delivered positive performance as we continue to execute against our strategic transformation.

Join us tomorrow at 7:30 a.m. CST for our Q3 2024 earnings conference call webcast. Register here:

With support from ASPR, NC DOT and our local team, a second temporary bridge is now installed and operational at North Cove. This bridge will enable more truck and equipment traffic to enter and leave the site. Latest updates: #NorthCoveStrong

We’ve restarted our first IV fluids line at our North Cove site. Thanks to the Baxter team and our remediation partners for their hard work and dedication, and the ongoing support of government agencies. Latest: #NorthCoveStrong